01 / Mechanism

What it actually does.

Metformin is a small, positively-charged biguanide that accumulates inside mitochondria, where it inhibits Complex I of the electron transport chain. This drops mitochondrial ATP production, raises cellular AMP (adenosine monophosphate), and indirectly activates AMPK (AMP-activated protein kinase) — the master cellular energy sensor [Rena 2017]. A 2025 paper in Science Advances confirmed Complex I as the principal glucose-lowering target in vivo using a Complex-I-blind metformin analog [Liu 2025].

That single mechanism feeds three downstream effects: suppression of hepatic gluconeogenesis (the main glucose-lowering action), increased peripheral insulin sensitivity, and a remodeling of the gut microbiome that boosts GLP-1 (glucagon-like peptide-1) secretion and GDF-15 (growth differentiation factor 15) release from the intestinal lining [Coll 2020]. GDF-15 is now believed to drive much of the modest weight loss and appetite suppression that metformin produces.

The geroscience interest stems from AMPK activation overlapping with calorie-restriction signaling and mTOR (mechanistic target of rapamycin) inhibition — two of the most robust pro-longevity pathways in model organisms. Whether that translates in healthy humans is the open question TAME was designed to answer.

02 / Dosing

Standard titration schedule.

Week	Dose	Indication	Note
1–2	500 mg with dinner	Initiation	GI-sensitive — start with food
3–4	500 mg twice daily	T2D titration	Breakfast + dinner
5–8	1000 mg twice daily	T2D maintenance	Effective glycemic dose
Longevity (off-label)	500–1500 mg/day	Off-label	Lower doses to avoid blunting exercise adaptation
XR formulations	500–2000 mg once daily	GI intolerance	Glumetza, Fortamet — better tolerability

Exercise interaction

Two 2019 trials (MASTERS) suggested metformin can blunt the mitochondrial-adaptation response to aerobic exercise in older adults — possibly cutting VO₂ max gains in half. The longevity case rests partly on AMPK activation; if you're already activating AMPK through exercise, adding metformin may be redundant or counterproductive. Time dosing away from training, or skip on heavy-training days.

03 / Contraindications

Who should not take this.

eGFR < 30 mL/min/1.73m². Absolute contraindication. Lactic acidosis risk rises sharply in severe renal impairment. Dose reduction below eGFR 45.
Acute or unstable heart failure. Tissue hypoperfusion raises lactic acid; compensated CHF is generally fine.
Severe liver disease or active alcohol use disorder. Impaired lactate clearance.
Iodinated contrast imaging. Hold metformin at the time of contrast in patients with eGFR 30–60; resume 48 hours after with renal recheck.
Pre-operative. Hold the morning of surgery — fasting + hypoperfusion risk.
Severe acute illness, sepsis, dehydration. Anything that compromises tissue oxygen delivery raises lactic acidosis risk.

04 / Side effects

What to expect.

GI upset (~25%). Diarrhea, nausea, metallic taste. Mitigations: take with food, use the XR formulation, start lower, escalate slower.
Vitamin B12 depletion. Real and dose/duration-dependent. ~10–30% of long-term users develop measurable B12 deficiency over 5+ years. Recheck B12 annually; supplement 500 mcg/day if levels drift below 400 pg/mL.
Lactic acidosis (rare). ~3–10 cases per 100,000 patient-years on label. Almost always linked to dosing in the setting of acute renal failure or hypoperfusion. Symptoms: deep rapid breathing, muscle pain, unusual fatigue.
Modest weight neutrality or 1–3 kg loss. Not a primary weight-loss agent — but unlike sulfonylureas, doesn't cause weight gain.
Potential blunting of exercise adaptation. Seen in older-adult resistance training cohorts; less clear in younger populations.

05 / Off-label longevity use

The case, and the caveats.

The longevity case rests on three legs. First, retrospective cohort data: a 2014 UK study of diabetics on metformin found they outlived matched non-diabetic controls — surprising, given diabetes itself shortens life. A 2025 target-trial emulation in older women with T2D found metformin associated with greater odds of reaching age 90 versus sulfonylureas [Ho 2025]. Second, mechanistic overlap with AMPK activation, mild mitochondrial uncoupling, and microbiome remodeling — all pathways implicated in lifespan extension in model organisms. Third, the MILES trial (Metformin In Longevity Study) showed metformin partially reversed an age-related gene-expression signature in muscle and adipose tissue of older non-diabetic adults after 12 weeks [Kulkarni 2018].

The TAME trial (Targeting Aging with Metformin) was designed to be the definitive prospective RCT — 3,000 adults aged 65–79, primary endpoint a composite of cardiovascular disease, cancer, cognitive decline, and mortality [Barzilai 2016]. As of 2025 it remains partially funded and has not enrolled; the NIA committed ~$5M of an estimated $45–70M budget. Until TAME (or an equivalent) reads out, the longevity case is suggestive, not proven.

Compared to GLP-1s for cardiometabolic protection, metformin is much weaker on weight but much cheaper, with a longer safety track record and a plausible direct geroprotective mechanism. See the GLP-1 era long read for how the first-line conversation in T2D is shifting.

06 / Cost

Honest pricing.

Source	Form	~Monthly cost (USD)	Note
Generic IR	500 mg, 1000 mg tablets	$4–$15	Walmart $4 list, GoodRx ~$8
Generic XR	500 mg, 750 mg, 1000 mg	$12–$40	Better GI tolerance
Brand	Glumetza, Fortamet	$1,000+	Almost no one pays this
Telehealth (off-label)	500 mg, 1000 mg	$25–$60 with consult	Longevity-clinic markup

Generic metformin is one of the cheapest prescription drugs in modern medicine. The longevity-clinic premium is for the consult and prescription, not the molecule.

07 / Key references

The evidence base.

Rena G et al. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. [Rena 2017]
Liu Y et al. Metformin targets mitochondrial complex I to lower blood glucose levels. Science Advances. 2025;11(eads5466). [Liu 2025]
Coll AP et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444–448. [Coll 2020]
Kulkarni AS et al. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults (MILES). Aging Cell. 2018;17(2):e12723. [Kulkarni 2018]
Barzilai N et al. Metformin as a Tool to Target Aging. Cell Metabolism. 2016;23(6):1060–1065. [Barzilai 2016]
Ho VW et al. Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation. J Gerontol A Biol Sci Med Sci. 2025. [Ho 2025]
Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (Diabetes Prevention Program). NEJM. 2002;346(6):393–403. [DPP 2002]
UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865. [UKPDS 1998]

About this profile

Last reviewed against evidence: 2026-05-12. This profile is editorial reference content, not sponsored. Wellness Radar does not run affiliate links on prescription drugs. The author is an informed synthesizer, not a clinician — decisions about metformin belong to you and a physician who knows your full medical history, including kidney function and B12 status.

Metformin